Patients and Caregivers

About CA125 + HE4

Know the right treatment path.

CA125 + HE4 accurately stratified 89% of all epithelial ovarian tumors and low malignant potential tumors as high risk and 75% of all benign disease as low risk.

In a recent study, it was discovered that women with a pelvic mass who had elevated levels of a substance called HE4 in their blood were more likely to have ovarian cancer, and that this substance has a complementary relationship to CA125. A follow-up study demonstrated that the combination of the two tests allowed physicians to accurately stratify women with a pelvic mass as having a high or low risk for an ovarian malignancy.

The test combines the results of CA125 and HE4 using an algorithm to determine the risk for an ovarian malignancy in patients who present with a pelvic mass. This is an important and exciting new development in ovarian cancer research because it can help steer patients down the right treatment path for optimal care.

How does the test work?

CA125 + HE4 are blood tests that use the combination of 2 test results and a statistical calculation to determine a patient’s risk of malignancy. Menopausal status affects the risk value so two values are provided: one for pre- and one for postmenopausal patients.

Physicians can utilize this test, in combination with other information (physical, pelvic, and/or transvaginal exams) to identify patients with a high risk for malignancy who may have a better outcome when treated by a gynecologic oncologist.